The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.
John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
Successes With T-DXd and the Need for Continued Research in Brain Metastasis
June 13th 2024In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.
Read More